1201 Clinical and Pathologic Risk Factors for Lymph Node Metastases in Gastric Neuroendocrine Tumors

2019 ◽  
Vol 114 (1) ◽  
pp. S675-S675
Author(s):  
Jonathan Ragheb ◽  
Firas Bahdi ◽  
Neal Mehta ◽  
Robert Butler ◽  
Prabhleen Chahal ◽  
...  
2021 ◽  
Author(s):  
Denghui Wang ◽  
Jiang Zhu ◽  
Chang Deng ◽  
Zhixin Yang ◽  
Daixing Hu ◽  
...  

Abstract Objective: Few studies have evaluated the influence of HT and Multifocality on central lymph node metastases(CLNM) and lateral lymph node metastases(LLNM) of PTC. The present study focused on risk factors for lymph node metastasis in PTC according to the presence of HT or multifocality. Materials and methods:1413 patients were identified.The relationship between HT or multifocality and lymph nodemetastasis was analyzed by univariate and multivariate logistic regression, ROC curves were constructed to show the predictive effect of each variable on the target outcome.Results: The PTCs with HT were more likely to be multifocal.(40.0% versus 17.5%,P <0.001). Compared to MPTC without HT, MPTC with HT showed a lower number of metastatic CLNs and LLNs (P < 0.05). HT was identifified as an independent protective factor for CLNM in all PTC patients (OR, 0.480; 95% CI, 0.359-0.643; P< .001) and in MPTC patients (OR, 0.094; 95% CI, 0.044-0.204; P < 0.001), the multicocality was independent risk factors for CLNM(OR, 2.316; 95% CI, 1.667-3.217; P< 0.001) and LLNM(OR, 2.004; 95% CI, 1.469-2.733; P< 0.001).The variables concluded HT or MPTC were screened to predict CLNM in all patients, CLNM in patients with MPTC and LLNM in all patients (AUCs: 0.731, 0.843 and 0.696, respectively, P < 0.0001). The two type of diseases existed concurrently may result in the decrease of CLNM and LLNM, AUCs of ROC to predict CLNM and LLNM are 0.696 and 0.63(P<0.0001). Conclusions: Our study identified multifocality as an independent risk factor predicting CLNM and LLNM in PTC patients. HT was proven to be a protective factor that reduced the CLNM risk in all patients and in patients with MPTC. The existence of both type of diseases can result in the reduction of CLNM and LLNM.


2017 ◽  
Vol 27 (8) ◽  
pp. 1694-1700 ◽  
Author(s):  
Kitty Pavlakis ◽  
Alexandros Rodolakis ◽  
Stylianos Vagios ◽  
Zannis Voulgaris ◽  
Irini Messini ◽  
...  

2015 ◽  
Vol 101 (1) ◽  
pp. 58-65 ◽  
Author(s):  
Michelle Kang Kim ◽  
Richard R.P. Warner ◽  
Stephen C. Ward ◽  
Noam Harpaz ◽  
Sasan Roayaie ◽  
...  

2012 ◽  
Vol 78 (11) ◽  
pp. 1215-1218 ◽  
Author(s):  
Qingqing He ◽  
Dayong Zhuang ◽  
Luming Zheng ◽  
Ziyi Fan ◽  
Peng Zhou ◽  
...  

The aim of this study was to evaluate outcomes for patients with papillary thyroid microcarcinoma (PTMC) treated at a single institution during a 162-month period and to determine which patients need aggressive treatment. Two hundred seventy-three patients with PTMC had subtotal or total thyroidectomy 1 prophylactic or therapeutic lymph node dissection. Clinical and histopathological characteristics of 273 patients were identified and statistically analyzed. The tumors were multifocal in 36.3 per cent of the patients with PTMCs. Fifty-six per cent had neck lymph node metastases at diagnosis. Large-sized tumor (over 5 mm), age older than 45 years, multifocality, bilaterality, and extrathyroidal extension were associated with subclinical central lymph node metastases. Ninety-six patients older than 45 years of age were upgraded from Stage I to III or IVA. Ten patients with lateral node recurrence or local recurrence in the residual thyroid had one or more risk factors. The high rates of multifocality and Level VI area subclinical lymph node metastasis were two important clinical and histopathological characteristics of PTMC. Patients who had one or more risk factors should receive more aggressive surgical management.


Surgery ◽  
2019 ◽  
Vol 166 (1) ◽  
pp. 15-21 ◽  
Author(s):  
Alexandra G. Lopez-Aguiar ◽  
Cecilia G. Ethun ◽  
Mohammad Y. Zaidi ◽  
Flavio G. Rocha ◽  
George A. Poultsides ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document